Reports
Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.
Global Human Insulin Market: By Product Type: Drugs, Delivery Device; By Type: Insulin Analogs and Biosimilars, Delivery Device; By Brand: Humalog, Insuman, Humulin, Others; By Delivery Device; By Application; Regional Analysis; Historical Market and Forecast (2017-2027); Competitive Landscape; Industry Events and Developments
Global Human Insulin Market Outlook
The global human insulin market attained USD 36 billion in 2020. The market is expected to grow at a CAGR of 4.7% in the forecast period of 2022-2027 to attain USD 48 billion by 2026.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Rising Incidence of Diabetes in North America to Aid the Market Growth of Human Insulin
The market for human insulin is expected to be driven by the growing demand from the North America region over the forecast period. This could be attributed to the rising incidence of diabetes and the increasing geriatric population, which are majorly contributing to the rising demand for human insulin in the region. On the basis of revenue, many countries in Europe like Germany, France, and Italy are predicted to contribute considerably to the growth of the human insulin industry over the forecast period. Meanwhile, the Asia Pacific region is expected to be a favourable market for human insulin over the forecast period. This could be ascribed to the growing research and development activities undertaken by various organisations and rising government initiatives in the region.
Human Insulin: Market Segmentation
Human insulin is referred to the synthetic insulin, which is grown in the laboratory and simulates the insulin in humans. The function of insulin is to regulate fat and carbohydrate metabolism in the body. It was developed through the 1960s and 1970s and finally approved for pharmaceutical use in 1982.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
On the basis of product type, the market is divided into:
- Drugs
- Delivery Device
Based on type, the industry can be segmented into:
- Insulin Analogs and Biosimilars
- Delivery Device
Insulin analogs and biosimilars is further divided on the basis of types into long acting, rapid acting, and pre-mixed, whereas delivery device is divided into intermediate-acting, short-acting, pre-mixed.
By brand, the industry is categorised into:
- NovoRapid/Novolog
- Humalog
- Insuman
- Humulin
- Lantus
- Actrapid, Insulatard, and Mixtard
- Others
On the basis of delivery service, the industry is segregated into:
- Pens
- Syringes
- Pen Needles
- Others
Based on applications, the industry is divided into:
- Type 1
- Type 2
The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Rising Investments in R&D Activities to Aid the Market Growth of Human Insulin
The market for human insulin is driven by the rising cases of diabetes and obesity across the globe, which are the resultants of changing lifestyles and unhealthy consumption of sugar in various food and beverages. In addition, the rising investments in research and development activities by several organisations have led to an advanced and easier way of injecting insulin, which is also boosting the market growth of human insulin. Moreover, the introduction of the safety pen devices and pen needles for effective delivery of insulin is propelling the global market forward. Further, growing awareness of diabetes is expected to bolster the demand in the human insulin industry.
Key Industry Players in the Global Human Insulin Market
The report gives a detailed analysis of the following key players in the global human insulin market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
- Nova Nordisk A/S
- Biocon Limited
- Sanofi S.A.
- Pfizer Inc.
- Eli Lilly and Company
- Others
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2020 |
| Historical Period | 2017-2021 |
| Forecast Period | 2022-2027 |
| Scope of the Report | Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Product Type, Type, Brand, Delivery Device, Application, Region |
| Breakup by Product Type | Drugs, Delivery Device |
| Breakup by Type | Insulin Analogs and Biosimilars, Delivery Device |
| Breakup by Brand | NovoRapid/Novolog, Humalog, Insuman, Humulin, Lantus, Actrapid, Insulatard, and Mixtard, Others |
| Breakup by Delivery Device | Pens, Syringes, Pen Needles, Others |
| Breakup by Application | Type 1, Type 2 |
| Breakup by Region | North America, Latin America, Europe, Middle East and Africa, Asia Pacific |
| Market Dynamics | SWOT, Porter's Five Forces, Key Indicators for Price and Demand |
| Competitive Landscape | Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications |
| Companies Covered | Nova Nordisk A/S, Biocon Limited, Sanofi S.A., Pfizer Inc., Eli Lilly and Company, Others |
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 Global
6.2 Regional
7 Industry Opportunities and Challenges
8 Global Human Insulin Market Analysis
8.1 Key Industry Highlights
8.2 Global Human Insulin Historical Market (2017-2021)
8.3 Global Human Insulin Market Forecast (2022-2027)
8.4 Global Human Insulin Market by Product Type
8.4.1 Drugs
8.4.1.1 Market Share
8.4.1.2 Historical Trend (2017-2021)
8.4.1.3 Forecast Trend (2022-2027)
8.4.2 Delivery Device
8.4.2.1 Market Share
8.4.2.2 Historical Trend (2017-2021)
8.4.2.3 Forecast Trend (2022-2027)
8.5 Global Human Insulin Market by Type
8.5.1 Insulin Analogs and Biosimilars
8.5.1.1 Market Share
8.5.1.2 Historical Trend (2017-2021)
8.5.1.3 Forecast Trend (2022-2027)
8.5.1.4 Breakup by Type
8.5.1.4.1 Long Acting
8.5.1.4.1.1 Market Share
8.5.1.4.1.2 Historical Trend (2017-2021)
8.5.1.4.1.3 Forecast Trend (2022-2027)
8.5.1.4.2 Rapid Acting
8.5.1.4.2.1 Market Share
8.5.1.4.2.2 Historical Trend (2017-2021)
8.5.1.4.2.3 Forecast Trend (2022-2027)
8.5.1.4.3 Pre-mixed
8.5.1.4.3.1 Market Share
8.5.1.4.3.2 Historical Trend (2017-2021)
8.5.1.4.3.3 Forecast Trend (2022-2027)
8.5.2 Delivery Device
8.5.2.1 Market Share
8.5.2.2 Historical Trend (2017-2021)
8.5.2.3 Forecast Trend (2022-2027)
8.5.2.4 Breakup by Type
8.5.2.4.1 Intermediate-Acting
8.5.2.4.1.1 Market Share
8.5.2.4.1.2 Historical Trend (2017-2021)
8.5.2.4.1.3 Forecast Trend (2022-2027)
8.5.2.4.2 Short-Acting
8.5.2.4.2.1 Market Share
8.5.2.4.2.2 Historical Trend (2017-2021)
8.5.2.4.2.3 Forecast Trend (2022-2027)
8.5.2.4.3 Pre-Mixed
8.5.2.4.3.1 Market Share
8.5.2.4.3.2 Historical Trend (2017-2021)
8.5.2.4.3.3 Forecast Trend (2022-2027)
8.6 Global Human Insulin Market by Brand
8.6.1 NovoRapid/Novolog
8.6.1.1 Market Share
8.6.1.2 Historical Trend (2017-2021)
8.6.1.3 Forecast Trend (2022-2027)
8.6.2 Humalog
8.6.2.1 Market Share
8.6.2.2 Historical Trend (2017-2021)
8.6.2.3 Forecast Trend (2022-2027)
8.6.3 Insuman
8.6.3.1 arket Share
8.6.3.2 Historical Trend (2017-2021)
8.6.3.3 Forecast Trend (2022-2027)
8.6.4 Humulin
8.6.4.1 Market Share
8.6.4.2 Historical Trend (2017-2021)
8.6.4.3 Forecast Trend (2022-2027)
8.6.5 Lantus
8.6.5.1 Market Share
8.6.5.2 Historical Trend (2017-2021)
8.6.5.3 Forecast Trend (2022-2027)
8.6.6 Actrapid, Insulatard, and Mixtard
8.6.6.1 Market Share
8.6.6.2 Historical Trend (2017-2021)
8.6.6.3 Forecast Trend (2022-2027)
8.6.7 Others
8.7 Global Human Insulin Market by Delivery Device
8.7.1 Pens
8.7.1.1 Market Share
8.7.1.2 Historical Trend (2017-2021)
8.7.1.3 Forecast Trend (2022-2027)
8.7.2 Syringes
8.7.2.1 Market Share
8.7.2.2 Historical Trend (2017-2021)
8.7.2.3 Forecast Trend (2022-2027)
8.7.3 Pen Needles
8.7.3.1 Market Share
8.7.3.2 Historical Trend (2017-2021)
8.7.3.3 Forecast Trend (2022-2027)
8.7.4 Others
8.8 Global Human Insulin Market by Application
8.8.1 Type 1
8.8.1.1 Market Share
8.8.1.2 Historical Trend (2017-2021)
8.8.1.3 Forecast Trend (2022-2027)
8.8.2 Type 2
8.8.2.1 Market Share
8.8.2.2 Historical Trend (2017-2021)
8.8.2.3 Forecast Trend (2022-2027)
8.9 Global Human Insulin Market by Region
8.9.1 Market Share
8.9.1.1 North America
8.9.1.2 Europe
8.9.1.3 Asia Pacific
8.9.1.4 Latin America
8.9.1.5 Middle East and Africa
9 Regional Analysis
9.1 North America
9.1.1 Historical Trend (2017-2021)
9.1.2 Forecast Trend (2022-2027)
9.1.3 Breakup by Country
9.1.3.1 United States of America
9.1.3.2 Canada
9.2 Europe
9.2.1 Historical Trend (2017-2021)
9.2.2 Forecast Trend (2022-2027)
9.2.3 Breakup by Country Kingdom
9.2.3.1 United
9.2.3.2 Germany
9.2.3.3 France
9.2.3.4 Italy
9.2.3.5 Others
9.3 Asia Pacific
9.3.1 Historical Trend (2017-2021)
9.3.2 Forecast Trend (2022-2027)
9.3.3 Breakup by Country
9.3.3.1 China
9.3.3.2 Japan
9.3.3.3 India
9.3.3.4 ASEAN
9.3.3.5 Australia
9.3.3.6 Others
9.4 Latin America
9.4.1 Historical Trend (2017-2021)
9.4.2 Forecast Trend (2022-2027)
9.4.3 Breakup by Country
9.4.3.1 Brazil
9.4.3.2 Argentina
9.4.3.3 Mexico
9.4.3.4 Others
9.5 Middle East and Africa
9.5.1 Historical Trend (2017-2021)
9.5.2 Forecast Trend (2022-2027)
9.5.3 Breakup by Country
9.5.3.1 Saudi Arabia
9.5.3.2 United Arab Emirates
9.5.3.3 Nigeria
9.5.3.4 South Africa
9.5.3.5 Others
10 Market Dynamics
10.1 SWOT Analysis
10.1.1 Strengths
10.1.2 Weaknesses
10.1.3 Opportunities
10.1.4 Threats
10.2 Porter’s Five Forces Analysis
10.2.1 Supplier’s Power
10.2.2 Buyer’s Power
10.2.3 Threat of New Entrants
10.2.4 Degree of Rivalry
10.2.5 Threat of Substitutes
10.3 Key Indicators for Demand
10.4 Key Indicators for Price
11 Value Chain Analysis
12 Competitive Landscape
12.1 Market Structure
12.2 Company Profiles
12.2.1 Nova Nordisk A/S
12.2.1.1 Company Overview
12.2.1.2 Product Portfolio
12.2.1.3 Demographic Reach and Achievements
12.2.1.4 Certifications
12.2.2 Biocon Limited
12.2.2.1 Company Overview
12.2.2.2 Product Portfolio
12.2.2.3 Demographic Reach and Achievements
12.2.2.4 Certifications
12.2.3 Sanofi S.A.
12.2.3.1 Company Overview
12.2.3.2 Product Portfolio
12.2.3.3 Demographic Reach and Achievements
12.2.3.4 Certifications
12.2.4 Pfizer Inc.
12.2.4.1 Company Overview
12.2.4.2 Product Portfolio
12.2.4.3 Demographic Reach and Achievements
12.2.4.4 Certifications
12.2.5 Eli Lilly and Company
12.2.5.1 Company Overview
12.2.5.2 Product Portfolio
12.2.5.3 Demographic Reach and Achievements
12.2.5.4 Certifications
12.2.6 Others
13 Industry Events and Developments
List of Key Figures and Tables
1. Global Human Insulin Market: Key Industry Highlights, 2016 and 2026
2. Global Human Insulin Historical Market: Breakup by Product Type (USD Billion), 2017-2021
3. Global Human Insulin Market Forecast: Breakup by Product Type (USD Billion), 2022-2027
4. Global Human Insulin Historical Market: Breakup by Type (USD Billion), 2017-2021
5. Global Human Insulin Market Forecast: Breakup by Type (USD Billion), 2022-2027
6. Global Human Insulin Historical Market: Breakup by Brand (USD Billion), 2017-2021
7. Global Human Insulin Market Forecast: Breakup by Brand (USD Billion), 2022-2027
8. Global Human Insulin Historical Market: Breakup by Delivery Device (USD Billion), 2017-2021
9. Global Human Insulin Market Forecast: Breakup by Delivery Device (USD Billion), 2022-2027
10. Global Human Insulin Historical Market: Breakup by Application (USD Billion), 2017-2021
11. Global Human Insulin Market Forecast: Breakup by Application (USD Billion), 2022-2027
12. Global Human Insulin Historical Market: Breakup by Region (USD Billion), 2017-2021
13. Global Human Insulin Market Forecast: Breakup by Region (USD Billion), 2022-2027
14. North America Human Insulin Historical Market: Breakup by Country (USD Billion), 2017-2021
15. North America Human Insulin Market Forecast: Breakup by Country (USD Billion), 2022-2027
16. Europe Human Insulin Historical Market: Breakup by Country (USD Billion), 2017-2021
17. Europe Human Insulin Market Forecast: Breakup by Country (USD Billion), 2022-2027
18. Asia Pacific Human Insulin Historical Market: Breakup by Country (USD Billion), 2017-2021
19. Asia Pacific Human Insulin Market Forecast: Breakup by Country (USD Billion), 2022-2027
20. Latin America Human Insulin Historical Market: Breakup by Country (USD Billion), 2017-2021
21. Latin America Human Insulin Market Forecast: Breakup by Country (USD Billion), 2022-2027
22. Middle East and Africa Human Insulin Historical Market: Breakup by Country (USD Billion), 2017-2021
23. Middle East and Africa Human Insulin Market Forecast: Breakup by Country (USD Billion), 2022-2027
24. Global Human Insulin Market Structure
Key Questions Answered in the Report
In 2020, the global human insulin market attained a value of nearly USD 36 billion.
The market is projected to grow at a CAGR of 4.7% between 2022 and 2027.
The industry is primarily being driven by the growing incidences of health issues such as obesity, changing consumer lifestyles, increased investments in research and development of advanced insulin injection mechanisms, and the availability of safety pen devices and pen needles for optimal insulin delivery.
The key trends boosting the market growth are the rising incidences of diabetes and the increasing geriatric population.
The major regions in the industry are North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.
The significant product types include drugs and delivery device.
The major types of the product include insulin analogs and biosimilars, and delivery device.
The significant brands include NovoRapid/Novolog, Humalog, Insuman, Humulin, Lantus, Actrapid, Insulatard, and Mixtard, and others.
The different delivery devices include pens, syringes, pen needles, and others.
The major applications of the product include Type 1 and Type 2.
The major players in the industry are Nova Nordisk A/S, Biocon Limited, Sanofi S.A., Pfizer Inc., Eli Lilly and Company, and others.
Analyst Review
The global human insulin market attained a value of USD 36 billion in 2020, driven by the rising incidence of diabetes and the increasing geriatric population. Aided by the growing medical and biotechnology industries, the market is expected to witness a further growth in the forecast period of 2022-2027, growing at a CAGR of 4.7%.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on product type, the global human insulin industry can be segmented into drugs and delivery device. By type, the industry can be divided into insulin analogs and biosimilars, and delivery device. Based on brand, the market can be divided into NovoRapid/Novolog, Humalog, Insuman, Humulin, Lantus, Actrapid, Insulatard, and Mixtard, and others. By delivery device, the market can be classified into pens, syringes, pen needles, and others. On the basis of application, the market can be categorised into type 1 and type 2. The major regional markets for human insulin are North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific. The key players in the above market include Nova Nordisk A/S, Biocon Limited, Sanofi S.A., Pfizer Inc., Eli Lilly and Company, and others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$1499
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$2699-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateFive User License
$3699-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$4699-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
The growing geriatric population drives the global adalimumab biosimilar market. Aided by the rising incidence of rheumatoid arthritis and the proliferation of skin disorders, the market is expected t...
The India biosimilar market size reached a value of almost USD 633 million in the year 2020. The market is further expected to grow at a CAGR of 11% between 2021 and 2026.
The global prothrombin complex concentrate (PCC) market is being driven by the clinical advantage of PCC over fresh frozen plasma in the historical period. Aided by the widespread use of vitamin K ant...
The global biosimilar market size reached a value of almost USD 16.6 billion in the year 2020. The biosimilar market is further expected to grow at a CAGR of 18.1% between 2021 and 2026 to reach a val...
The Europe biosimilar market attained a value of USD 2,945 million in the year 2020 driven by the growing geriatric population in the region. Aided by the low cost of the product and the expected expi...
NEWSLETTER